These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 12820334)

  • 1. Biochemical relapse of prostate cancer. Evidence after radical surgery.
    Prott FJ; Spitz J; Michaelis M; Niles B; Barth S; Köllermann M; Kleinschmidt K
    Anticancer Res; 2003; 23(2A):979-81. PubMed ID: 12820334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy.
    Shen S; Lepor H; Yaffee R; Taneja SS
    J Urol; 2005 Mar; 173(3):777-80. PubMed ID: 15711268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Supersensitive PSA-analysis after radical prostatectomy: a powerful tool to reduce the time gap between surgery and evidence of biochemical failure.
    Haese A; Huland E; Graefen M; Huland H
    Anticancer Res; 1999; 19(4A):2641-4. PubMed ID: 10470210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of ultrasensitive prostate-specific antigen assay for early detection of biochemical failure after radical prostatectomy.
    Nakamura M; Hasumi H; Miyoshi Y; Sugiura S; Fujinami K; Yao M; Kubota Y; Uemura H
    Int J Urol; 2005 Dec; 12(12):1050-4. PubMed ID: 16409609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate specific antigen nadir determined using ultra-sensitive prostate specific antigen as a predictor of biochemical progression after radical prostatectomy in Japanese males.
    Kinoshita H; Kamoto T; Nishiyama H; Nakamura E; Matsuda T; Ogawa O
    Int J Urol; 2007 Oct; 14(10):930-4; discussion 934. PubMed ID: 17880291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy.
    Gonzalez CM; Roehl KA; Antenor JV; Blunt LW; Han M; Catalona WJ
    Urology; 2004 Oct; 64(4):723-8. PubMed ID: 15491709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship of ultrasensitive measurements of prostate-specific antigen levels to prostate cancer recurrence after radical prostatectomy.
    Taylor JA; Koff SG; Dauser DA; McLeod DG
    BJU Int; 2006 Sep; 98(3):540-3. PubMed ID: 16925750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
    Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
    Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant radiotherapy in locally confined prostate cancer.
    Schäfer U; Witt F; Micke O; Willich N
    Anticancer Res; 2003; 23(2A):983-5. PubMed ID: 12820335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early detection of prostate cancer with low PSA cut-off values leads to significant stage migration in radical prostatectomy specimens.
    Berger AP; Spranger R; Kofler K; Steiner H; Bartsch G; Horninger W
    Prostate; 2003 Oct; 57(2):93-8. PubMed ID: 12949932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [PSA and follow-up after treatment of prostate cancer].
    Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
    Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inadequacy of prostate-specific antigen doubling time estimates calculated using an ultrasensitive assay of prostate-specific antigen for biochemical failure after radical prostatectomy.
    Shimizu F; Matsuyama Y; Tominaga T; Ohashi Y; Fujime M
    Urol Int; 2007; 79(4):356-60. PubMed ID: 18025856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
    Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
    Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does benign prostatic tissue contribute to measurable PSA levels after radical prostatectomy?
    Godoy G; Tareen BU; Lepor H
    Urology; 2009 Jul; 74(1):167-70. PubMed ID: 19406457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK; Levy LB; Cheung R; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years.
    Postma R; de Vries SH; Roobol MJ; Wildhagen MF; Schröder FH; van der Kwast TH
    Cancer; 2005 Feb; 103(4):708-16. PubMed ID: 15648082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure.
    Blana A; Brown SC; Chaussy C; Conti GN; Eastham JA; Ganzer R; Murat FJ; Pasticier G; Rebillard X; Rewcastle JC; Robertson CN; Thuroff S; Ward JF
    BJU Int; 2009 Oct; 104(8):1058-62. PubMed ID: 19388986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.